ATE228851T1 - ACELLULAR PERTUSSIS VACCINES AND METHOD FOR PRODUCING - Google Patents
ACELLULAR PERTUSSIS VACCINES AND METHOD FOR PRODUCINGInfo
- Publication number
- ATE228851T1 ATE228851T1 AT96911886T AT96911886T ATE228851T1 AT E228851 T1 ATE228851 T1 AT E228851T1 AT 96911886 T AT96911886 T AT 96911886T AT 96911886 T AT96911886 T AT 96911886T AT E228851 T1 ATE228851 T1 AT E228851T1
- Authority
- AT
- Austria
- Prior art keywords
- pref
- iii
- pertussis
- toxoid
- agg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Vaccine for protecting humans against Bordetella pertussis infection comprises pertussis toxoid (I), filamentous haemagglutinin (II), pertactin (III) and agglutinogens (IV) of B. pertussis in relative amts. able to confer protection to >= 70% of an at-risk population. A single dose is 5-30 mu g (I) and (II), 3-15 mu g (III) and 1-10 mu g (IV), all expressed as nitrogen contents, esp. 10 mu g (I) and 5 mu g (II) or 20 mu g each of these, plus 5 mu g (III) and 3 mu g (IV). Vaccines are administered by subcutaneous or intramuscular injection. (IV) comprises fimbrial agglutinogens (Agg) 2 and 3 (pref. at ratio 1.5-2:1) but is free of Agg 1. These may also include diphtheria toxoid, pref. at 15 Lfs, and tetanus toxoid, pref. at 5 Lf, opt. also other non-Bordetella antigens. They can also include an adjuvant, specifically alum.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/433,646 US5877298A (en) | 1995-05-04 | 1995-05-04 | Acellular pertussis vaccines and methods of preparing thereof |
| US50174395A | 1995-07-12 | 1995-07-12 | |
| PCT/CA1996/000278 WO1996034623A1 (en) | 1995-05-04 | 1996-05-02 | Acellular pertussis vaccines and methods of preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE228851T1 true ATE228851T1 (en) | 2002-12-15 |
Family
ID=27029924
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96911886T ATE228851T1 (en) | 1995-05-04 | 1996-05-02 | ACELLULAR PERTUSSIS VACCINES AND METHOD FOR PRODUCING |
| AT03078355T ATE496634T1 (en) | 1995-05-04 | 1996-05-02 | ACELLULAR PERTUSSIS VACCINES AND METHOD FOR THE PRODUCTION THEREOF |
| AT96911887T ATE221081T1 (en) | 1995-05-04 | 1996-05-02 | ACELLULAR PERTUSSIS VACCINES AND METHOD FOR THE PRODUCTION THEREOF |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03078355T ATE496634T1 (en) | 1995-05-04 | 1996-05-02 | ACELLULAR PERTUSSIS VACCINES AND METHOD FOR THE PRODUCTION THEREOF |
| AT96911887T ATE221081T1 (en) | 1995-05-04 | 1996-05-02 | ACELLULAR PERTUSSIS VACCINES AND METHOD FOR THE PRODUCTION THEREOF |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6399076B2 (en) |
| EP (7) | EP1405643A1 (en) |
| CN (2) | CN100387618C (en) |
| AT (3) | ATE228851T1 (en) |
| AU (2) | AU710538B2 (en) |
| BR (2) | BR9608115A (en) |
| CA (3) | CA2220063C (en) |
| DE (3) | DE69622555T2 (en) |
| DK (3) | DK0826001T3 (en) |
| ES (2) | ES2182971T3 (en) |
| FR (1) | FR16C0015I2 (en) |
| LU (1) | LU93036I2 (en) |
| MX (1) | MX9708481A (en) |
| NL (1) | NL300804I2 (en) |
| NZ (2) | NZ306391A (en) |
| PT (3) | PT826001E (en) |
| WO (2) | WO1996034623A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2646776B1 (en) * | 1989-05-12 | 1994-06-03 | Pasteur Institut | USE OF VACCINANT PREPARATIONS BASED ON ADENYL CYCLASE OR OF BACTERIA PRODUCING THEM AS PROTECTIVE ANTIGENS AGAINST THE EFFECTS OF BORDETELLA |
| US6051240A (en) * | 1994-04-28 | 2000-04-18 | Takeda Chemical Industries, Ltd. | Method of separating protective components of Bordetella pertussis |
| US6696065B1 (en) * | 1995-05-04 | 2004-02-24 | Aventis Pastuer Limited | Acellular pertussis vaccines and methods of preparation thereof |
| GB9611501D0 (en) * | 1996-06-03 | 1996-08-07 | Smithkline Beecham Biolog | Vaccine compositions |
| DK0914153T3 (en) * | 1996-07-02 | 2007-01-29 | Sanofi Pasteur Ltd | Multivalent DTP polio vaccines |
| AU774649B2 (en) * | 1998-10-21 | 2004-07-01 | Kitasato Daiichi Sankyo Vaccine Co.,Ltd. | Vaccine preparations containing attenuated toxin |
| WO2005051985A2 (en) * | 2003-11-20 | 2005-06-09 | Sanofi Pasteur, Inc. | Methods for purifying pertussis toxin and peptides useful therefor |
| NZ555889A (en) * | 2004-12-17 | 2009-07-31 | Staat Der Nederlanden Vert Doo | Deacylation of LPS in gram negative bacteria |
| PL1942932T3 (en) * | 2005-08-08 | 2013-11-29 | Univ Oregon Health & Science | Inactivating pathogens with hydrogen peroxide for vaccine production |
| EP1867638A1 (en) * | 2006-06-16 | 2007-12-19 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Procedure for the Conection of two Molecules via Diels-Alder Reactions with Inverse Electron Demand |
| EA015964B1 (en) | 2006-09-07 | 2012-01-30 | Глаксосмитклайн Байолоджикалс С.А. | Vaccine |
| CN100537767C (en) * | 2007-04-29 | 2009-09-09 | 中国药品生物制品检定所 | Recombinant expressed and the application of pertussis vaccine protective antigen |
| GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| US20100330158A1 (en) * | 2009-03-31 | 2010-12-30 | Innopharma, Llc | Protein-assisted drug delivery system for the targeted administration of active agents |
| EP2430040A1 (en) | 2009-05-11 | 2012-03-21 | Novartis AG | Antigen purification process for pertactin antigen |
| WO2013043608A1 (en) * | 2011-09-20 | 2013-03-28 | Bio-Rad Laboratories, Inc. | Removal of virucidal agents from biomolecule preparations |
| WO2013049535A2 (en) | 2011-09-30 | 2013-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Influenza vaccine |
| CN102584958A (en) * | 2012-02-08 | 2012-07-18 | 北京天坛生物制品股份有限公司 | Purification method for 69KD outer membrane protein of pertussis bacillus |
| CN102793915B (en) * | 2012-07-25 | 2013-10-23 | 天津康希诺生物技术有限公司 | Production method of acellular pertussis vaccine |
| CN105007936B (en) * | 2013-03-08 | 2018-10-02 | 扬森疫苗与预防公司 | acellular pertussis vaccine |
| SG10201911134QA (en) | 2015-06-05 | 2020-01-30 | Grace W R & Co | Adsorbent bioprocessing clarification agents and methods of making and using the same |
| CN105106947A (en) * | 2015-07-21 | 2015-12-02 | 华兰生物工程股份有限公司 | Acellular pertussis vaccine detoxified with hydrogen peroxide and preparation method thereof |
| EP4070815A1 (en) | 2016-10-03 | 2022-10-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Hiv-1 env fusion peptide immunogens and their use |
| US11202824B2 (en) | 2016-10-31 | 2021-12-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptide fragments from filoviruses and their uses |
| EP3600405A1 (en) | 2017-03-24 | 2020-02-05 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Glycan-masked engineered outer domains of hiv-1 gp120 and their use |
| KR102426041B1 (en) * | 2017-08-01 | 2022-07-29 | 주식회사 녹십자 | Method for obtaining bordetella pertussis related protein comprising processes of freezing and thawing |
| EP3697440A1 (en) | 2017-10-16 | 2020-08-26 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
| US12053519B2 (en) | 2018-09-23 | 2024-08-06 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use |
| WO2020086483A1 (en) | 2018-10-22 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant gp120 protein with v1-loop deletion |
| CN110358802B (en) * | 2019-08-16 | 2021-06-18 | 长春百克生物科技股份公司 | Method for removing pertussis component fimbrin 2/3 endotoxin |
| US12210017B2 (en) | 2020-01-08 | 2025-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptides representing epitopes from filoviruses |
| CN112094354B (en) * | 2020-11-05 | 2021-02-02 | 苏州世诺生物技术有限公司 | Acinetobacter paragallinarum genetic engineering subunit vaccine, preparation method and application thereof |
| AU2022323509A1 (en) | 2021-08-03 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection |
| US20250197455A1 (en) | 2022-03-27 | 2025-06-19 | TThe United States of America, as represented by the Secretary, Department of Health and Human Servi | Base-covered hiv-1 envelope ectodomains and their use |
| CN117417419B (en) * | 2023-01-10 | 2024-04-19 | 康希诺生物股份公司 | A pertussis toxin detoxification method and acellular diphtheria, tetanus and pertussis combined vaccine |
| WO2024249626A1 (en) | 2023-05-30 | 2024-12-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 envelope triple tandem trimers and their use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4258029A (en) | 1979-04-23 | 1981-03-24 | Connaught Laboratories Limited | Synthetic adjuvants for stimulation of antigenic responses |
| DE3521994A1 (en) | 1985-06-20 | 1987-01-02 | Bayer Ag | N- (2-AMINOACYLAMIDO-2-DESOXY-HEXOSYL) -AMIDES, CARBAMATES AND UREAS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS |
| GB8601279D0 (en) * | 1986-01-20 | 1986-02-26 | Public Health Lab Service | Purification of pertussis antigens |
| US4705686A (en) | 1986-05-09 | 1987-11-10 | American Cyanamid | Process for the preparation of acellular Bordetalla pertussis vaccine |
| WO1989001976A1 (en) * | 1987-09-04 | 1989-03-09 | Amgen Inc. | Recombinant dna-derived bordetella toxin subunit analogs |
| GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
| GB8807860D0 (en) | 1988-04-05 | 1988-05-05 | Connaught Lab | Pertussis vaccine |
| US4967176A (en) * | 1988-07-15 | 1990-10-30 | Raychem Corporation | Assemblies of PTC circuit protection devices |
| US5101014A (en) | 1989-02-10 | 1992-03-31 | United States Of America | Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis |
| EP0474646A4 (en) * | 1989-03-31 | 1992-10-21 | Washington University | Bordetella vaccines |
| US5276142A (en) | 1989-12-11 | 1994-01-04 | American Cyanamid Company | Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis |
| GB9007657D0 (en) * | 1990-04-04 | 1990-05-30 | Connaught Lab | Purification of a pertussis outer membrane protein(omp69) |
| EP0484621A3 (en) * | 1990-07-11 | 1992-08-26 | American Cyanamid Company | Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens |
| US6051240A (en) | 1994-04-28 | 2000-04-18 | Takeda Chemical Industries, Ltd. | Method of separating protective components of Bordetella pertussis |
| FR2728170A1 (en) * | 1994-12-15 | 1996-06-21 | Pasteur Institut | ANTI-BORDETELLA CELL-LIKE VACCINE |
| US5877298A (en) * | 1995-05-04 | 1999-03-02 | Connaught Lab | Acellular pertussis vaccines and methods of preparing thereof |
-
1996
- 1996-05-02 EP EP20030078354 patent/EP1405643A1/en not_active Withdrawn
- 1996-05-02 WO PCT/CA1996/000278 patent/WO1996034623A1/en active IP Right Grant
- 1996-05-02 AT AT96911886T patent/ATE228851T1/en active
- 1996-05-02 BR BR9608115-5A patent/BR9608115A/en not_active Application Discontinuation
- 1996-05-02 DK DK96911887T patent/DK0826001T3/en active
- 1996-05-02 NZ NZ306391A patent/NZ306391A/en not_active IP Right Cessation
- 1996-05-02 CN CNB961952296A patent/CN100387618C/en not_active Expired - Lifetime
- 1996-05-02 EP EP03078355A patent/EP1393744B1/en not_active Expired - Lifetime
- 1996-05-02 DK DK96911886T patent/DK0824358T3/en active
- 1996-05-02 MX MX9708481A patent/MX9708481A/en active IP Right Grant
- 1996-05-02 DE DE69622555T patent/DE69622555T2/en not_active Expired - Lifetime
- 1996-05-02 AT AT03078355T patent/ATE496634T1/en active
- 1996-05-02 DE DE69625191T patent/DE69625191T2/en not_active Expired - Lifetime
- 1996-05-02 WO PCT/CA1996/000279 patent/WO1996034883A1/en active IP Right Grant
- 1996-05-02 EP EP02012064A patent/EP1234580A1/en not_active Withdrawn
- 1996-05-02 PT PT96911887T patent/PT826001E/en unknown
- 1996-05-02 CA CA002220063A patent/CA2220063C/en not_active Expired - Lifetime
- 1996-05-02 NZ NZ306392A patent/NZ306392A/en not_active IP Right Cessation
- 1996-05-02 AT AT96911887T patent/ATE221081T1/en active
- 1996-05-02 CN CN96195230A patent/CN1198099A/en active Pending
- 1996-05-02 ES ES96911886T patent/ES2182971T3/en not_active Expired - Lifetime
- 1996-05-02 CA CA002220048A patent/CA2220048C/en not_active Expired - Lifetime
- 1996-05-02 PT PT03078355T patent/PT1393744E/en unknown
- 1996-05-02 CA CA002433502A patent/CA2433502A1/en not_active Abandoned
- 1996-05-02 PT PT96911886T patent/PT824358E/en unknown
- 1996-05-02 EP EP02012063A patent/EP1234579A1/en not_active Withdrawn
- 1996-05-02 EP EP02077074.9A patent/EP1233022B1/en not_active Expired - Lifetime
- 1996-05-02 US US08/945,750 patent/US6399076B2/en not_active Expired - Lifetime
- 1996-05-02 AU AU54941/96A patent/AU710538B2/en not_active Expired
- 1996-05-02 ES ES96911887T patent/ES2180758T3/en not_active Expired - Lifetime
- 1996-05-02 AU AU54940/96A patent/AU715417B2/en not_active Expired
- 1996-05-02 EP EP96911886A patent/EP0824358B1/en not_active Expired - Lifetime
- 1996-05-02 BR BR9608114-7A patent/BR9608114A/en not_active Application Discontinuation
- 1996-05-02 DE DE69638326T patent/DE69638326D1/en not_active Expired - Lifetime
- 1996-05-02 DK DK03078355.9T patent/DK1393744T3/en active
- 1996-05-02 EP EP96911887A patent/EP0826001B1/en not_active Expired - Lifetime
-
2016
- 2016-04-21 LU LU93036C patent/LU93036I2/en unknown
- 2016-04-27 FR FR16C0015C patent/FR16C0015I2/en active Active
- 2016-04-28 NL NL300804C patent/NL300804I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE228851T1 (en) | ACELLULAR PERTUSSIS VACCINES AND METHOD FOR PRODUCING | |
| AU4267093A (en) | Vaccine compositions for mucosal delivery | |
| RU99101850A (en) | POLYVALENT ASSOCIATED DECOMPOSITION-DIPHTHERIUM-CENTRAL (DTP) -POLIOMYELITIC VACCINES | |
| BR9712917A (en) | Acellular pertussis vaccine with diphtheria and tetanus toxoids | |
| EP0761230A3 (en) | Vaccine containing Bordetella pertussis outer membrane protein, and method of making such vaccine | |
| CA2427475A1 (en) | Purification of hbv antigens for use in vaccines | |
| LU91155I2 (en) | Combination of diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous hemagglutininin, pertactin, pertussis fimbrial agglutinogens 2 and 3 and inactivated poliovirus type 1, type 2 and type 3. | |
| ATE149569T1 (en) | METHOD FOR PRODUCING VACCINES OR TOXOIDS | |
| CA2092420A1 (en) | Vaccine Suitable for Combatting Bordetella Pertussis | |
| BR9909076A (en) | Attenuated measles virus, recombinantly generated, isolated, measles virus, human respiratory syncytial virus (rsv), subgroup b, attenuated, recombinantly generated, isolated, rsv, subgroup b, vaccine process for immunizing an individual to induce protection against virus measles, process for immunizing an individual to induce protection against rsv, subgroup b, composition, process for producing attenuated infectious measles virus, process for producing attenuated infectious rsv subgroup b | |
| WO1997046255A3 (en) | Vaccine composition comprising outer membrane protein fragments of bordetella pertussis | |
| MXPA99004278A (en) | Acellular pertussisvaccine with diphthriae- and tetanus-toxoids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0824358 Country of ref document: EP |